EpiBiologics
EpiBiologics Raises $107M Series B | Protein Degradation Platform
EpiBiologics Closes $107M Series B
EpiBiologics, developing tissue-selective extracellular protein degradation therapeutics, has raised $107 million in Series B funding.
Key Highlights
- Novel protein degradation approach
- Tissue-selective targeting
- Strong biotech investor support
Company Overview
EpiBiologics is developing a new class of therapeutics that selectively degrade disease-causing proteins outside of cells, opening new therapeutic possibilities for previously undruggable targets.
Company Info
Investors (2)
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free